|Bid||285.00 x 200|
|Ask||285.16 x 100|
|Day's Range||280.24 - 291.91|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||17.90|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biogen popped early Tuesday after its spinal drug nearly tripled expectations in the second quarter, leading to a 4% guidance boost.
Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.
Strong sales for its spinal muscular atrophy (SMA) drug, Spinraza, also spurred the U.S. drugmaker to raise its 2017 profit and revenue forecasts. Spinraza could become one of the company's "largest commercial assets, shifting the center of gravity for Biogen beyond MS", CEO Michel Vounatsos said in a post-earnings conference call.